• English

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

    Educational Notifications


    The Maryland Prescription Drug Monitoring Program (PDMP),  collects information on all Schedule II – V controlled dangerous substance (CDS) prescriptions dispensed in Maryland, and makes these data available to authorized end users. In addition to disclosing data when solicited by authorized users, the Maryland PDMP may also proactively notify certain individuals or entities when outlying patient or prescriber behavior is identified. Unsolicited Reporting is the activity of analyzing PDMP data for an indicator of concern and then proactively reporting PDMP data to a specific individual or entity based on the analysis finding.

    Unsolicited reporting is considered a national best practice and has been adopted by a majority of states. Under HB025 (Chapter 531, Prescription Drug Monitoring Program – Revisions, 2019), the Office of the PDMP is required to review prescription monitoring data for indications of possible misuse or abuse of a prescription drug by a patient; possible violations of law and possible breaches of professional standards by a prescriber or a dispenser and provide education to providers who are identified.  

    The letters, also referred to as Unsolicited Reporting Notifications or URNs, are provided for educational and practice improvement purposes with the goal of supporting clinical decision-making and reducing the risk of adverse outcomes for patients receiving CDS prescriptions. The letters are not public record. Providers should use their clinical judgement in interpreting the URNs and within the context of the provider's patient panel, patients' history, diagnosis, care plan, involvement with hospice, or complex pain management needs. Each URN sent by the Program includes educational resources.

    Since 2016, the Office of the PDMP has been sending URNs through the mail based on the address prescribers provide to the DEA; in 2022 the Program began shifting to sending URNs electronically.


    The Office of the PDMP works closely with the PDMP Technical Advisory Committee (TAC) in determining which metrics to use in assessing the PDMP data for possible misuse or abuse of a prescription drug, possible violations of law, and possible breaches of professional standards by a provider. The TAC consists of MDH-Secretary appointed clinicians who serve as subject matter experts on CDS prescribing and dispensing (Health-General Article section 21-2a-07). Each month, the Office of the PDMP analyzes the PDMP data for possible concerning behaviors on behalf of a patient or provider based on clinical guidance provided by the TAC.

    TAC LOGO.jpg